Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase i to improve activation of the anticancer prodrug CB1954

Biochemical Pharmacology

Volumn 84, Issue 6, 2012, Pages 775-783

  Swe, P M ^a,c   Copp, J N ^a   Green, L K ^a   Guise, C P ^b   Mowday, A M ^b   Smaill, J B ^b   Patterson, A V ^b   Ackerley, D F ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

CB1954; Directed evolution; Enzyme prodrug therapy; Nitroreductase; SOS response

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; FLAVIN REDUCTASE 1; MUTANT PROTEIN; OXIDOREDUCTASE; TRETAZICAR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER GENE THERAPY; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IC 50; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ENGINEERING; SITE DIRECTED MUTAGENESIS; VIBRIO FISCHERI; WILD TYPE;

ALIIVIBRIO FISCHERI; ANTINEOPLASTIC AGENTS; AZIRIDINES; BACTERIAL PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; ESCHERICHIA COLI; FMN REDUCTASE; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; PRODRUGS; SOS RESPONSE (GENETICS);

EID: 84864924162     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.07.002     Document Type: Article

References (40)

1. W.A. Denny Prodrug strategies in cancer therapy Eur J Med Chem 36 2001 577 595
2. N. Schellmann, P.M. Deckert, D. Bachran, H. Fuchs, and C. Bachran Targeted enzyme prodrug therapies Mini Rev Med Chem 10 2010 887 904
3. N.G. Rainov A phase III clinical evaluation of HSV thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum Gene Ther 11 2000 2389 2401
4. A.V. Patterson, M. Saunders, and O. Greco Prodrugs in genetic chemoradiotherapy Curr Pharm Des 9 2003 2131 2154
5. G.U. Dachs, M.A. Hunt, S. Syddall, D.C. Singleton, and A.V. Patterson Bystander or no bystander for gene directed enzyme prodrug therapy Molecules 14 2009 4517 4545
6. G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, and J. Baddeley Virus-directed enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug CB1954 Clin Cancer Res 7 2001 2662 2668
7. D.C. Singleton, D. Li, S.Y. Bai, S.P. Syddall, J.B. Smaill, and Y. Shen The nitroreductase prodrug SN28343 enhances the potency of armed oncolytic adenovirus ONYX-411(NTR) Cancer Gene Ther 14 2007 953 967
8. P. Patel, J.G. Young, V. Mautner, D. Ashdown, S. Bonney, and R.G. Pineda A phase I/II clinical trial in localized prostate cancer of adenovirus expressing nitroreductase with CB1954 Mol Ther 17 2009 1292 1299
9. T.J. Harvey, I.M. Hennig, S.D. Shnyder, P.A. Cooper, N. Ingram, and G.D. Hall Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo Cancer Gene Ther 18 2011 773 784
10. C.L. White, T. Menghistu, K.R. Twigger, P.F. Searle, S.A. Bhide, and R.G. Vile Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo Gene Ther 15 2008 424 433
11. A.N. Lukashev, C. Fuerer, M.J. Chen, P. Searle, and R. Iggo Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954 Hum Gene Ther 16 2005 1473 1483
12. D. Onion, P. Patel, R.G. Pineda, N. James, and V. Mautner Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer Hum Gene Ther 20 2009 1249 1258
13. G.A. Prosser, J.N. Copp, S.P. Syddall, E.M. Williams, J.B. Smaill, and W.R. Wilson Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 Biochem Pharmacol 79 2010 678 687
14. P.R. Race, A.L. Lovering, S.A. White, J.I. Grove, P.F. Searle, and C.W. Wrighton Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954 J Mol Biol 368 2007 481 492
15. J.I. Grove, A.L. Lovering, C. Guise, P.R. Race, C.J. Wrighton, and S.A. White Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954 Cancer Res 63 2003 5532 5537
16. M. Jaberipour, S.O. Vass, C.P. Guise, J.I. Grove, R.J. Knox, and L. Hu Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations Biochem Pharmacol 79 2010 102 111
17. C.P. Guise, J.I. Grove, E.I. Hyde, and P.F. Searle Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle Gene Ther 14 2007 690 698
18. G.A. Prosser, A.V. Patterson, and D.F. Ackerley uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954 J Biotechnol 150 2010 190 194
19. S.O. Vass, D. Jarrom, W.R. Wilson, E.I. Hyde, and P.F. Searle E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 Br J Cancer 100 2009 1903 1911
20. C.D. Emptage, R.J. Knox, M.J. Danson, and D.W. Hough Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation Biochem Pharmacol 77 2009 21 29
21. J. Theys, O. Pennington, L. Dubois, G. Anlezark, T. Vaughan, and A. Mengesha Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo Br J Cancer 95 2006 1212 1219
22. Y. Barak, S.H. Thorne, D.F. Ackerley, S.V. Lynch, C.H. Contag, and A. Matin New enzyme for reductive cancer chemotherapy YieF, and its improvement by directed evolution Mol Cancer Ther 5 2006 97 103
23. W. Wang, and B.A. Malcolm Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis Biotechniques 26 1999 680 682
24. S.N. Ho, H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R. Pease Site-directed mutagenesis by overlap extension using the polymerase chain reaction Gene 77 1989 51 59
25. S. Hobbs, S. Jitrapakdee, and J.C. Wallace Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins Biochem Biophys Res Commun 252 1998 368 372
26. S. Zenno, K. Saigo, H. Kanoh, and S. Inouye Identification of the gene encoding the major NAD(P)H-flavin oxidoreductase of the bioluminescent bacterium Vibrio fischeri ATCC 7744 J Bacteriol 176 1994 3536 3543
27. S. Zenno, H. Koike, M. Tanokura, and K. Saigo Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution J Bacteriol 178 1996 4731 4733
28. H. Koike, H. Sasaki, T. Kobori, S. Zenno, K. Saigo, and M.E. Murphy 1.8 crystal structure of the major NAD(P)H:FMN oxidoreductase of a bioluminescent bacterium Vibrio fischeri: overall structure, cofactor and substrate-analog binding, and comparison with related flavoproteins J Mol Biol 280 1998 259 273
29. A. Pavelka, E. Chovancova, and J. Damborsky HotSpot Wizard: a web server for identification of hot spots in protein engineering Nucleic Acids Res 37 Web Server issue 2009 W376 W383
30. M.T. Reetz, and J.D. Carballeira Iterative saturation mutagenesis (ISM) for rapid directed evolution of functional enzymes Nat Protoc 2 2007 891 903
31. M: a useful comparator? Trends Biotechnol 25 2007 247 249
32. S. Lutz Beyond directed evolution - semi-rational protein engineering and design Curr Opin Biotechnol 21 2010 734 743
33. G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, and J. Baddeley Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954 Clin Cancer Res 7 2001 2662 2668
34. C. Schmidt-Dannert, and F.H. Arnold Directed evolution of industrial enzymes Trends Biotechnol 17 1999 135 136
35. D. Jarrom, M. Jaberipour, C.P. Guise, S. Daff, S.A. White, and P.F. Searle Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954 Biochemistry 48 2009 7665 7672
36. m cyclophosphamide 4-hydroxylase P450 2B11 Mol Cancer Ther 5 2006 541 555
37. S.W. Linwu, C.A. Wu, F.C. Peng, and A.H. Wang Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis Biochem Pharmacol March 2012 [Epub ahead of print]
38. N.S. Forbes Engineering the perfect (bacterial) cancer therapy Nat Rev Cancer 10 2010 785 794
39. V.V. Gwenin, C.D. Gwenin, and M. Kalaji Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy Langmuir 27 2011 14300 14307
40. W.L. DeLano The PyMOL molecular graphics system 2002 DeLano Scientific San Carlos, CA, USA www.pymol.org